Krish Ramadurai is a Partner at Harmonix Fund and leads the firm’s technical due diligence, investment sourcing, and portfolio operational support across their healthcare, life sciences, and deep technology practices. At Harmonix, he manages a top-decile performing portfolio of 40+ companies with an enterprise value of over $7 Billion with numerous major scientific breakthroughs, including the world’s first AI-designed drug to enter clinical trials to the launch of the first commercial rideshare satellite into space. He is a multi-published author, advisor, lecturer, and former researcher at Harvard & MIT, who has published three internationally released books on applied engineering and medicine. He is a board observer for Sorcero and xCures and a venture advisor for Nucleate and the National Venture Capital Association.